Knowles Julius's Form 4 filing
Keros Therapeutics, Inc. (KROS) · filed Jan 20, 2023
- Accession no.
- 0001209191-23-004279
- Filed
- Jan 20, 2023
- Trade date
- Apr 13, 2020
- Filing delay
- 1,012 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $25.0K. It was filed 1012 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Knowles JuliusCIK 0001808365 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2020 | Common Stock | PPurchaseAcquired | +1,191 | $20.98 | +$24,987.18 | 1,191 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.